Esperion Stock Surges 57% as ARCHIMED Acquires Company for $1.1 Billion
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
/ 352 items
#XY Event-Driven Stocks↓
FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio
Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.
Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Rocket Scores $180 Million Cash Boost – Extends Runway to 2028 for Heart Gene Therapies
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.